Rapid Micro Biosystems Appoints Michael Beaulieu as Vice President, Investor Relations and Corporate Communications

0

LOWELL, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life science technology company providing critical automation solutions to facilitate the efficient manufacturing and rapid and safe launch of healthcare products, today announced the appointment of Michael Beaulieu as Vice President, Investor Relations and Corporate Communications.

“We are delighted to welcome Mike to the Rapid Micro team,” said Sean Wirtjes, Chief Financial Officer. “He brings a deep understanding of the healthcare investment community that will be invaluable as we continue to expand our reach and engagement and build awareness of our automated microbial QC solution. We are confident that his established relationships with various stakeholders, including institutional investors, will assist us in these efforts and in our goal of creating long-term value for our shareholders. »

Beaulieu brings over two decades of experience in investor relations, communications and equity research. Most recently, he served as Head of Investor Relations at Integra LifeSciences Holding Corporation (“Integra”). At Integra, he was named to the US Institutional Investor Team, Top IR Professionals for Life Sciences and Diagnostic Tools and Medical Supplies and Devices. Previously, he was a senior equity research analyst at AIG SunAmerica, PNC Advisors and Merrill Lynch Investment Managers. Beaulieu holds a BS from the University of Vermont, an MBA from Fordham Gabelli School of Business and is a Chartered Financial Analyst.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life science technology company that provides mission-critical automation solutions to facilitate the efficient manufacturing and rapid, safe release of healthcare products such as biologics, vaccines, cell therapies and genes and sterile injectables. The company’s flagship Growth Direct System automates and modernizes outdated manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations around the world. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of in-line/on-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations and faster decision-making, which customers rely on to ensure a safe and consistent supply of important healthcare products. The company is headquartered and manufactured in the United States in Lowell, Massachusetts, with global sites in Switzerland, Germany and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the company on Twitter at @rapidmicrobio Or on LinkedIn.

CONTACT: Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications [email protected] Media Contact: [email protected]
Share.

Comments are closed.